Peptidomimetic

Peptidomimetic designates a molecule engineered to mimic the biological activity and target-binding properties of a peptide while improving drug-like characteristics such as stability, oral bioavailability, and resistance to enzymatic degradation. These compounds retain key structural features required for receptor or enzyme binding but incorporate chemical modifications including non-natural backbones, constrained conformations, or substituted functional groups that reduce protease susceptibility and enhance pharmacokinetic performance.

The pharmaceutical industry develops peptidomimetics to overcome limitations of natural peptide therapeutics, which often suffer from rapid degradation, poor membrane permeability, and short half-life. Peptidomimetics have achieved major clinical success, particularly in protease inhibitor development where early HIV therapies used peptide-like scaffolds optimised for potency and stability. Rational design relies on structural biology and structure-activity relationships identifying essential binding motifs while replacing unstable peptide bonds with bioisosteres. Applications span oncology, infectious diseases, cardiovascular medicine, and metabolic disorders where protein-protein interactions represent challenging targets accessible through peptide-inspired designs. As medicinal chemistry advances enable improved conformational control and synthetic flexibility, peptidomimetics continue bridging the gap between peptides and small molecules.